Barclays
KYMR icon

Barclays’s Kymera Therapeutics KYMR Stock Holding History

Barclays’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.6M Buy
85,679
+60,315
+238% +$6.91M ﹤0.01% 1667
2026
Q2 		$2.91M Buy
25,364
+11,117
+78% +$955K ﹤0.01% 2144
2026
Q1 		$1.19M Sell
14,247
-126,260
-90% -$10M ﹤0.01% 2654
2025
Q4 		$10.9M Sell
140,507
-14,637
-9% -$988K ﹤0.01% 1624
2025
Q3 		$8.78M Buy
155,144
+11,963
+8% +$540K ﹤0.01% 1765
2025
Q2 		$6.25M Buy
143,181
+57,969
+68% +$2M ﹤0.01% 1930
2025
Q1 		$2.33M Sell
85,212
-15,793
-16% -$576K ﹤0.01% 2515
2024
Q4 		$4.06M Buy
101,005
+9,250
+10% +$418K ﹤0.01% 2346
2024
Q3 		$4.34M Buy
91,755
+42,662
+87% +$1.88M ﹤0.01% 2209
2024
Q2 		$1.47M Sell
49,093
-270,808
-85% -$9.38M ﹤0.01% 2356
2024
Q1 		$12.9M Sell
319,901
-61,880
-16% -$2.21M ﹤0.01% 1228
2023
Q4 		$9.7M Sell
381,781
-7,695
-2% -$138K ﹤0.01% 1540
2023
Q3 		$5.41M Buy
389,476
+4,493
+1% +$90.3K ﹤0.01% 1286
2023
Q2 		$8.85M Buy
384,983
+25,055
+7% +$718K 0.01% 1041
2023
Q1 		$10.7M Sell
359,928
-30,722
-8% -$991K ﹤0.01% 1129
2022
Q4 		$9.8M Buy
390,650
+37,656
+11% +$1M ﹤0.01% 1220
2022
Q3 		$7.68M Buy
352,994
+119,857
+51% +$3.16M 0.01% 959
2022
Q2 		$4.59M Buy
233,137
+226,360
+3,340% +$5.29M ﹤0.01% 1391
2022
Q1 		$287K Buy
+6,777
New +$286K ﹤0.01% 3229

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays's KYMR Position: Q3 2026 in Review

Barclays increased its Kymera Therapeutics (KYMR) stake by 238% in Q3 2026, buying an estimated $6.91M and bringing the position to 85,679 shares worth $9.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1667.

Barclays first reported a position in KYMR in Q1 2022 and has held it in 19 quarters since. The position peaked at $12.9M in Q1 2024. 215 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Barclays held 85,679 shares of Kymera Therapeutics worth $9.6M as of Q3 2026.
  • Barclays bought 60,315 Kymera Therapeutics shares in Q3 2026, an estimated $6.91M.
  • Kymera Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1667 holding.
  • Barclays first reported a position in Kymera Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Kymera Therapeutics position peaked at $12.9M in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.